Who are Jiangsu Yahong Meditech's main competitors?

Named competitors: Zhaoke Ophthalmology (private or unlisted), Kanghong Pharmaceutical (002773.SZ). The cockpit's measured peer set (industry) also includes Strides Pharma Science (STAR.NS), Kissei Pharmaceutical (4547.T), Procter & Gamble Health (PGHL.NS), MoonLake Immunotherapeutics (MLTX), Zhejiang Garden Biopharmaceutical (300401.SZ), SSY (2005.HK).

Is Jiangsu Yahong Meditech expensive compared with its peers?

On ev / sales it trades at 17.8× against a peer median of 4.6×, most expensive of 17 in its peer set.

How has Jiangsu Yahong Meditech stock performed?

Over six months to 6 Nov 2026 the shares returned -11.8% against -13.9% for the median peer; over one year +15.0%.

← CockpitCompetitor Analysis › 688176.SS Jiangsu Yahong Meditech Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Yahong Meditech Co., Ltd. Class A688176.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.

≈ A small Chinese ophthalmology/CNS biotechMomentum strong 67

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$973M

US dollars, full cap

Free float

71%

of shares outstanding

$/day

$19.8M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-100.2 pp

WACC 8.1%

Hurdle

n/a

no reverse DCF

Next earnings

164 days

19 Apr 2027

Close · CNYCN¥11.34

1D-3.1%

1W+3.7%

1M-12.4%

3M+0.7%

6M-11.8%

YTD-1.5%

1Y+15.0%

ATR %6.3%

52w lowhigh37.4% off high

What Jiangsu Yahong Meditech does

Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.

In one line: A small Chinese ophthalmology/CNS biotech.

Products and services

Ophthalmology drug candidates
CNS drug candidates

Where it sits in the supply chain

Pharmaceuticals
Clinical-stage biotech
Ophthalmology and CNS

What could go right

Clinical trial data readouts

What could go wrong

Trial failure risk
Cash burn before approval

Moat: none (IP / patents). Pipeline-stage company whose value depends on unproven clinical trial outcomes.

Headquarters: Nantong, Jiangsu, China · Employees: 497

Named competitors

Zhaoke Ophthalmology private or unlisted
Kanghong Pharmaceutical 002773.SZ

Jiangsu Yahong Meditech at a glance

Size Jiangsu Yahong Meditech (688176.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $973M, the 2342nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.34 on 6 Nov 2026.

Performance Over six months the shares fell 11.8%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 19 in its peer set.

Growth Revenue grew 14.6% over the last twelve months (peer median +2.4%); the operating margin is -172.0% (peer median 5.8%).

Valuation It trades at 17.8× enterprise value to sales against a peer median of 4.6× (most expensive of 17).

Capital Return on invested capital runs 100.2 points below its cost of capital (8.1% WACC).

Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Jiangsu Yahong Meditech against the median of its 20 peers (local-currency closes).

Jiangsu Yahong Meditech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥320M	CN¥275M	CN¥201M	CN¥13.7M	CN¥26,095
Revenue growth	—	+37%	+1,360%	+52,560%	—
Gross profit	CN¥256M	CN¥181M	CN¥126M	-CN¥12.2M	-CN¥16.0M
EBITDA	n/a	-CN¥410M	-CN¥394M	-CN¥448M	-CN¥316M
Net income	-CN¥529M	-CN¥416M	-CN¥384M	-CN¥400M	-CN¥247M
Free cash flow	-CN¥556M	-CN¥431M	-CN¥431M	-CN¥500M	-CN¥269M
Capital expenditure	CN¥58.4M	CN¥19.1M	CN¥5.79M	CN¥102M	CN¥26.6M
Total debt	CN¥393M	CN¥345M	CN¥130M	CN¥134M	CN¥18.7M

Quarterly statements and history in the cockpit →

Jiangsu Yahong Meditech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Jiangsu Yahong Meditech is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Yahong Meditech is the large dot.

Jiangsu Yahong Meditech competitors and peer comparison

Head to head with its named competitors (688176.SS vs 002773.SZ)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
Jiangsu Yahong Meditech 688176.SS	$973M	-12%	+15%	-172%	17.8×	n/a
Chengdu Kanghong Pharmaceutical 002773.SZ	$3.18B	-7%	-11%	24%	3.6×	-2.2%

How Jiangsu Yahong Meditech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Yahong Meditech against its 20 peers (data as of 6 Nov 2026)
Measure	688176.SS	Peer median	Rank in peer set
1-month return	-12.4%	-6.6%	4th lowest of 20
6-month return	-11.8%	-13.9%	9th highest of 19
Distance from 52-week high	-37.4%	-30.2%	8th lowest of 21
Revenue growth (TTM)	+14.6%	+2.4%	5th highest of 18
Operating margin	-172.0%	5.8%	3rd lowest of 18
EV / Sales	17.8×	4.6×	most expensive of 17
ROIC minus cost of capital	-100.2 pp	-1.9 pp	lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Jiangsu Yahong Meditech 688176.SS	China	$973M	-12%	+15%	-172%	17.8×	n/a	n/a
Strides Pharma Science STAR.NS	India	$973M	-13%	+11%	14%	2.1×	18.1%	+7.8%
Kissei Pharmaceutical 4547.T	Japan	$973M	-16%	+6%	6%	1.1×	n/a	n/a
Procter & Gamble Health PGHL.NS	India	$971M	+4%	+13%	31%	6.3×	5.5%	+9.3%
MoonLake Immunotherapeutics MLTX	United States	$981M	-32%	n/a	n/a	n/a	n/a	n/a
Zhejiang Garden Biopharmaceutical 300401.SZ	China	$983M	-7%	+2%	24%	5.5×	10.2%	+13.4%
SSY 2005.HK	Hong Kong	$990M	+10%	-4%	12%	2.3×	2.1%	-0.5%
Savara SVRA	United States	$992M	-8%	n/a	n/a	n/a	n/a	n/a
Immatics IMTX	United States	$952M	-44%	-65%	-556%	10.7×	n/a	n/a
Harbin Gloria Pharmaceuticals 002437.SZ	China	$999M	-15%	-16%	13%	3.0×	8.8%	-6.9%
Northeast Pharmaceutical 000597.SZ	China	$948M	-10%	-6%	3%	1.0×	-6.8%	-0.7%
KPC Pharmaceuticals 600422.SS	China	$1.00B	-7%	-41%	-10%	1.9×	n/a	n/a
City Therapeutics CTY	United States	$944M	n/a	+388%	-442%	n/a	n/a	n/a
Hunan Warrant Pharmaceutical 688799.SS	China	$942M	-20%	+5%	9%	4.7×	n/a	n/a
Harrow HROW	United States	$1.01B	-30%	+21%	2%	4.4×	51.8%	+41.0%
Nxera Pharma 4565.T	Japan	$932M	+63%	+24%	14%	5.1×	16.2%	+27.3%
GuangYuYuan Chinese Herbal Medicine 600771.SS	China	$930M	-24%	-6%	5%	4.4×	33.2%	+4.2%
Dezhan Healthcare 000813.SZ	China	$928M	-18%	-10%	-121%	15.8×	n/a	n/a
Oscotec 039200.KS	South Korea	$1.02B	-30%	+233%	62%	8.3×	-9.5%	+18.1%
Guangxi Wuzhou Zhongheng 600252.SS	China	$1.03B	-11%	-43%	-42%	5.0×	11.9%	-13.7%
Symbiotec Pharmalab SYMBIOTEC.NS	India	$1.03B	n/a	n/a	n/a	n/a	n/a	n/a

Questions

Who are Jiangsu Yahong Meditech's main competitors?: Named competitors: Zhaoke Ophthalmology (private or unlisted), Kanghong Pharmaceutical (002773.SZ). The cockpit's measured peer set (industry) also includes Strides Pharma Science (STAR.NS), Kissei Pharmaceutical (4547.T), Procter & Gamble Health (PGHL.NS), MoonLake Immunotherapeutics (MLTX), Zhejiang Garden Biopharmaceutical (300401.SZ), SSY (2005.HK).
Is Jiangsu Yahong Meditech expensive compared with its peers?: On ev / sales it trades at 17.8× against a peer median of 4.6×, most expensive of 17 in its peer set.
How has Jiangsu Yahong Meditech stock performed?: Over six months to 6 Nov 2026 the shares returned -11.8% against -13.9% for the median peer; over one year +15.0%.